Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
Ann Oncol
    October 2025
  1. GOETZ MP, Toi M, Huober J, Sohn J, et al
    Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727].
    Ann Oncol. 2025 Oct 15:S0923-7534(25)00851-8. doi: 10.1016/j.annonc.2025.
    >> Share

  2. BURSTEIN HJ, Curigliano G, Gnant M, Loibl S, et al
    Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer.
    Ann Oncol. 2025 Oct 8:S0923-7534(25)04718-0. doi: 10.1016/j.annonc.2025.
    >> Share

    September 2025
  3. CHEN N, Freeman JQ, Yarlagadda S, Atmakuri A, et al
    Impact of Anthracyclines in Genomic High Risk, Node-Negative, HR-Positive/HER2-Negative Breast Cancer.
    Ann Oncol. 2025 Sep 17:S0923-7534(25)00922-6. doi: 10.1016/j.annonc.2025.
    >> Share

    August 2025
  4. CONTE PF, Dieci MV, Bisagni G, Schmid P, et al
    A-BRAVE trial: a Phase 3 randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients.
    Ann Oncol. 2025 Aug 28:S0923-7534(25)00925-1. doi: 10.1016/j.annonc.2025.
    >> Share

  5. TRAPANI D, Martins-Branco D, Curigliano G, Gennari A, et al
    Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline.
    Ann Oncol. 2025 Aug 12:S0923-7534(25)00914-7. doi: 10.1016/j.annonc.2025.
    >> Share

  6. GRAESER M, Gluz O, Zu Eulenburg C, Kuemmel S, et al
    Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials.
    Ann Oncol. 2025 Aug 4:S0923-7534(25)00913-5. doi: 10.1016/j.annonc.2025.
    >> Share

    July 2025
  7. VAN BAELEN K, Sawyer E, Van Cauwenberge J, Aftimos P, et al
    Clinical challenges and proposed solutions for patients with invasive lobular breast cancer.
    Ann Oncol. 2025 Jul 21:S0923-7534(25)00857-9. doi: 10.1016/j.annonc.2025.
    >> Share

  8. MAMANN A, Pradat Y, Bidard FC, Delaloge S, et al
    Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER+/HER2- breast cancer.
    Ann Oncol. 2025 Jul 5:S0923-7534(25)00830-0. doi: 10.1016/j.annonc.2025.
    >> Share

  9. PROVENZANO L, Dieci MV, Curigliano G, Giuliano M, et al
    Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study.
    Ann Oncol. 2025;36:762-774.
    >> Share

    June 2025
  10. HU Q, Yang X
    Navigating the Limits of Ribociclib in Early Breast Cancer: Questions from the NATALEE Trial.
    Ann Oncol. 2025 Jun 23:S0923-7534(25)00815-4. doi: 10.1016/j.annonc.2025.
    >> Share

  11. ZHU X, Zhu T, Gu X
    Letter Re: A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.
    Ann Oncol. 2025 Jun 20:S0923-7534(25)00816-6. doi: 10.1016/j.annonc.2025.
    >> Share

  12. LOIBL S, Nekljudova V, Denkert C
    Reply to Letter to the Editor "Final results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy-PENELOPE-B" by Sahin and Guven.
    Ann Oncol. 2025 Jun 10:S0923-7534(25)00167-X. doi: 10.1016/j.annonc.2025.
    >> Share

  13. ANDRE F, Tecson K, Egorov A
    Reply to Letter to the Editor: 'A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases' by Y. Liu & C. Zhang.
    Ann Oncol. 2025 Jun 10:S0923-7534(25)00193-0. doi: 10.1016/j.annonc.2025.
    >> Share

  14. TURNBULL C, Achatz MI, Balmana J, Castro E, et al
    Breast cancer germline multigene panel testing in mainstream oncology based on clinical-public health utility: ESMO Precision Oncology Working Group recommendations.
    Ann Oncol. 2025 Jun 9:S0923-7534(25)00172-3. doi: 10.1016/j.annonc.2025.
    >> Share

    May 2025
  15. LIU Y, Zhang C, Liu Y
    Letter to the editor 'A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases' by F. Andre et al.
    Ann Oncol. 2025 May 21:S0923-7534(25)00735-5. doi: 10.1016/j.annonc.2025.
    >> Share

  16. SAHIN TK, Guven DC
    Letter to the Editor - Final Survival Results from the Penelope-B trial investigating palbociclib vs placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy - PENELOPE-B.
    Ann Oncol. 2025 May 20:S0923-7534(25)00734-3. doi: 10.1016/j.annonc.2025.
    >> Share

    April 2025
  17. AKAMANDISA MP, Boddicker NJ, Yadav S, Hu C, et al
    Association of Gene Variant Type and Location with Breast Cancer Risk in the General Population.
    Ann Oncol. 2025 Apr 25:S0923-7534(25)00170-X. doi: 10.1016/j.annonc.2025.
    >> Share

  18. PAPAKONSTANTINOU A, Foukakis T
    Neoadjuvant treatment of HER2-positive breast cancer: Has the era of antibody-drug conjugates arrived?
    Ann Oncol. 2025 Apr 5:S0923-7534(25)00133-4. doi: 10.1016/j.annonc.2025.
    >> Share

  19. SANTUCCI C, Mignozzi S, Levi F, Malvezzi M, et al
    European cancer mortality predictions for the year 2025 with focus on breast cancer.
    Ann Oncol. 2025;36:460-468.
    >> Share

    March 2025
  20. ZENG X, Sun H, Wang Y
    Letter Re: Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial".
    Ann Oncol. 2025 Mar 30:S0923-7534(25)00126-7. doi: 10.1016/j.annonc.2025.
    >> Share

  21. LI JJ, Chen L, Shao ZM
    Response letter re: Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial.
    Ann Oncol. 2025 Mar 30:S0923-7534(25)00127-9. doi: 10.1016/j.annonc.2025.
    >> Share

  22. LOIBL S, Martin M, Bonnefoi H, Untch M, et al
    Final Survival Results from the Penelope-B trial investigating palbociclib vs placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy - PENELOPE-B.
    Ann Oncol. 2025 Mar 24:S0923-7534(25)00121-8. doi: 10.1016/j.annonc.2025.
    >> Share

  23. ANDERSEN L, Birkbak NJ
    Advancing ctDNA detection: Using whole-genome sequencing to power minimal residual disease monitoring in breast cancer.
    Ann Oncol. 2025 Mar 20:S0923-7534(25)00114-0. doi: 10.1016/j.annonc.2025.
    >> Share

  24. LI JJ, Wang ZH, Chen L, Zhang WJ, et al
    Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial.
    Ann Oncol. 2025 Mar 4:S0923-7534(25)00082-1. doi: 10.1016/j.annonc.2025.
    >> Share

    February 2025
  25. GARCIA-MURILLAS I, Abbott CW, Cutts RJ, Boyle SM, et al
    Whole genome sequencing powered ctDNA sequencing for breast cancer detection.
    Ann Oncol. 2025 Feb 4:S0923-7534(25)00053-5. doi: 10.1016/j.annonc.2025.
    >> Share

  26. CARAUSU M, Neven P, Ignatiadis M
    Expanding the role of CDK4/6 inhibitors in early breast cancer: insights from the NATALEE trial.
    Ann Oncol. 2025;36:127-129.
    >> Share

    January 2025
  27. ANDRE F, Solovieff N, Su F, Bardia A, et al
    Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials.
    Ann Oncol. 2025;36:54-64.
    >> Share

    December 2024
  28. FERNANDEZ-MARTINEZ A, Tanioka M, Ahn SG, Zagami P, et al
    Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2+ early breast cancer (EBC).
    Ann Oncol. 2024 Dec 18:S0923-7534(24)04989-5. doi: 10.1016/j.annonc.2024.
    >> Share

  29. CURIGLIANO G, Burstein HJ, Gnant M, Loibl S, et al
    Corrigendum to "Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023": [Annals of Oncology 34 (2023) 970-986].
    Ann Oncol. 2024 Dec 2:S0923-7534(24)04882-8. doi: 10.1016/j.annonc.2024.
    >> Share

  30. GOETZ MP, Andre V, Johnston SRD
    Response to letters to the Editor on 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3'.
    Ann Oncol. 2024;35:1202-1204.
    >> Share

    November 2024
  31. KIM J, Munster PN
    Estrogens and breast cancer.
    Ann Oncol. 2024 Nov 8:S0923-7534(24)04880-4. doi: 10.1016/j.annonc.2024.
    >> Share

    October 2024
  32. HUPPERT LA, Wolf D, Yau C, Brown-Swigart L, et al
    Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.
    Ann Oncol. 2024 Oct 28:S0923-7534(24)04070-5. doi: 10.1016/j.annonc.2024.
    >> Share

  33. HORTOBAGYI GN, Lacko A, Sohn J, Cruz F, et al
    A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial.
    Ann Oncol. 2024 Oct 21:S0923-7534(24)04064-X. doi: 10.1016/j.annonc.2024.
    >> Share

  34. MARTIN M, Stecklein SR, Gluz O, Villacampa G, et al
    TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy.
    Ann Oncol. 2024 Oct 15:S0923-7534(24)04061-4. doi: 10.1016/j.annonc.2024.
    >> Share

  35. COLLIER KA, Stover DG
    Confirmation of large BRCA2 reversion deletions leading to reconstituted in-frame transcripts detected via circulating tumor DNA.
    Ann Oncol. 2024;35:917-919.
    >> Share

    September 2024
  36. SAKAI H, Tsurutani J, Ozaki Y, Ishiguro H, et al
    A randomized, double-blind, placebo-controlled phase II study of olanzapine based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtec
    Ann Oncol. 2024 Sep 5:S0923-7534(24)03995-4. doi: 10.1016/j.annonc.2024.
    >> Share

  37. ANDRE F, Cortes J, Curigliano G, Modi S, et al
    A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases.
    Ann Oncol. 2024 Sep 4:S0923-7534(24)03928-0. doi: 10.1016/j.annonc.2024.08.2347.
    >> Share

  38. DE SANCTIS R, Bruzzi P, Zambelli A
    Unlocking Methodological Insights on Oncology Efficacy Endpoints: from Statistical to Clinical and Vice Versa. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer
    Ann Oncol. 2024 Sep 3:S0923-7534(24)03925-5. doi: 10.1016/j.annonc.2024.08.2345.
    >> Share

    August 2024
  39. DI MEGLIO A, Havas J, Pagliuca M, Franzoi MA, et al
    A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance two years later.
    Ann Oncol. 2024 Aug 2:S0923-7534(24)01517-5. doi: 10.1016/j.annonc.2024.
    >> Share

  40. LOBO-MARTINS S, Agostinetto E, de Azambuja E, Gebhart G, et al
    Tumour Heterogeneity in Molecular Imaging for Breast Cancer.
    Ann Oncol. 2024 Aug 2:S0923-7534(24)01515-1. doi: 10.1016/j.annonc.2024.
    >> Share

  41. SANCHEZ-BAYONA R, Oliveira M
    Overall survival in first-line HR+/HER2- advanced breast cancer in the era of CDK4/6 inhibitors.
    Ann Oncol. 2024;35:689-691.
    >> Share

  42. MIGLIACCIO I, Biganzoli L, Malorni L
    The new oral SERDs in endocrine-resistant breast cancer: who will benefit the most?
    Ann Oncol. 2024;35:683-685.
    >> Share

    July 2024
  43. ROWLANDS CF, Allen S, Balmana J, Domchek SM, et al
    Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing.
    Ann Oncol. 2024 Jul 8:S0923-7534(24)01014-7. doi: 10.1016/j.annonc.2024.
    >> Share

  44. FREEDMAN RA, Heiling HM, Li T, Trapani D, et al
    Neratinib and Ado-Trastuzumab-Emtansine for Pre-treated and Untreated HER2-positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium Trial 022.
    Ann Oncol. 2024 Jul 6:S0923-7534(24)01015-9. doi: 10.1016/j.annonc.2024.
    >> Share

  45. TARANTINO P, Tolaney SM
    Challenging immune exhaustion in early recurrent triple-negative breast cancer: pitfalls and hopes.
    Ann Oncol. 2024;35:579-581.
    >> Share

    June 2024
  46. ARECCO L, Bruzzone M, Bas R, Kim HJ, et al
    Impact of Hormone Receptor Status and Tumor Subtypes of Breast Cancer in Young BRCA Carriers.
    Ann Oncol. 2024 Jun 20:S0923-7534(24)00740-3. doi: 10.1016/j.annonc.2024.
    >> Share

  47. SHERRY AD, Lin TA, McCaw ZR, Ludmir EB, et al
    Interpretation of long-term survival data from MONARCH 3. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3' by M.
    Ann Oncol. 2024 Jun 3:S0923-7534(24)00718-X. doi: 10.1016/j.annonc.2024.
    >> Share

  48. ORLANDI A, Mastrantoni L, Bria E, Tortora G, et al
    To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall
    Ann Oncol. 2024 Jun 3:S0923-7534(24)00719-1. doi: 10.1016/j.annonc.2024.
    >> Share

    May 2024
  49. HAMILTON E, Oliveira M, Turner N, Garcia-Corbacho J, et al
    A Phase 1 dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.
    Ann Oncol. 2024 May 8:S0923-7534(24)00138-8. doi: 10.1016/j.annonc.2024.
    >> Share

  50. GOETZ MP, Toi M, Huober J, Sohn J, et al
    Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.
    Ann Oncol. 2024 May 8:S0923-7534(24)00139-X. doi: 10.1016/j.annonc.2024.
    >> Share

  51. DENT R, Andre F, Goncalves A, Martin M, et al
    IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer.
    Ann Oncol. 2024 May 7:S0923-7534(24)00107-8. doi: 10.1016/j.annonc.2024.
    >> Share

  52. PUSZTAI L, Denkert C, O'Shaughnessy J, Cortes J, et al
    Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
    Ann Oncol. 2024;35:429-436.
    >> Share

    April 2024
  53. PETERS S, Loi S, Andre F, Chandarlapaty S, et al
    Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions - a position statement from the ETOP IBCSG Partners Foundation.
    Ann Oncol. 2024 Apr 20:S0923-7534(24)00108-X. doi: 10.1016/j.annonc.2024.
    >> Share

    March 2024
  54. AGOSTINETTO E, Buisseret L, Salgado R, Kok M, et al
    Residual disease post neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: Does it help tailor adjuvant treatment?
    Ann Oncol. 2024 Mar 12:S0923-7534(24)00077-2. doi: 10.1016/j.annonc.2024.
    >> Share

    February 2024
  55. GENNARI A, Brain E, De Censi A, Nanni O, et al
    Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): Pilot study with 18F-Fluoroestradiol (18F-FES) CT/PET.
    Ann Oncol. 2024 Feb 27:S0923-7534(24)00057-7. doi: 10.1016/j.annonc.2024.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016